CN105764899B - Plk-4抑制剂的盐和晶型 - Google Patents

Plk-4抑制剂的盐和晶型 Download PDF

Info

Publication number
CN105764899B
CN105764899B CN201480064037.9A CN201480064037A CN105764899B CN 105764899 B CN105764899 B CN 105764899B CN 201480064037 A CN201480064037 A CN 201480064037A CN 105764899 B CN105764899 B CN 105764899B
Authority
CN
China
Prior art keywords
compound
cancer
fumarate
salt
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480064037.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105764899A (zh
Inventor
P·B·桑普森
M·费赫
H·W·鲍尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Priority to CN202110510808.4A priority Critical patent/CN113248486A/zh
Publication of CN105764899A publication Critical patent/CN105764899A/zh
Application granted granted Critical
Publication of CN105764899B publication Critical patent/CN105764899B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480064037.9A 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型 Active CN105764899B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110510808.4A CN113248486A (zh) 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18
US61/892,564 2013-10-18
PCT/CA2014/051001 WO2015054793A1 (en) 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110510808.4A Division CN113248486A (zh) 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型

Publications (2)

Publication Number Publication Date
CN105764899A CN105764899A (zh) 2016-07-13
CN105764899B true CN105764899B (zh) 2021-06-01

Family

ID=52827507

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480064037.9A Active CN105764899B (zh) 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型
CN202110510808.4A Pending CN113248486A (zh) 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110510808.4A Pending CN113248486A (zh) 2013-10-18 2014-10-17 Plk-4抑制剂的盐和晶型

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR102395737B1 (enExample)
CN (2) CN105764899B (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2639757T3 (es) 2010-04-06 2017-10-30 University Health Network Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales
DK3057965T3 (en) 2013-10-18 2019-04-01 Univ Health Network SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
CN111225670A (zh) * 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
WO2020215155A1 (en) * 2019-04-24 2020-10-29 University Health Network Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate
IL293623A (en) * 2019-12-06 2022-08-01 Univ Health Network Treatment of acute myeloid leukemia or myelodysplastic syndrome
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc Polo like kinase 4 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110559A1 (en) * 2006-03-29 2007-10-04 Pliva Hrvatska D.O.O. Pharmaceutically acceptable salts and polymorphic forms of sildenafil
CN101155791A (zh) * 2005-02-03 2008-04-02 拜耳先灵医药股份有限公司 作为极体样激酶（plk）抑制剂药剂的噻唑烷酮
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US8263596B2 (en) * 2010-04-06 2012-09-11 University Health Network Kinase inhibitors and method of treating cancer
WO2012121764A1 (en) * 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
CN103122001A (zh) * 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
US8481525B2 (en) * 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
WO2004037247A1 (en) 2002-10-21 2004-05-06 Irm Llc Oxindoles with anti-hiv activity
WO2008118097A1 (en) * 2007-03-23 2008-10-02 Agency For Science, Technology And Research Palladium catalysts
CN101970426A (zh) 2007-12-21 2011-02-09 大学健康网络 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2013053051A1 (en) * 2011-10-12 2013-04-18 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
DK3057965T3 (en) 2013-10-18 2019-04-01 Univ Health Network SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155791A (zh) * 2005-02-03 2008-04-02 拜耳先灵医药股份有限公司 作为极体样激酶（plk）抑制剂药剂的噻唑烷酮
WO2007110559A1 (en) * 2006-03-29 2007-10-04 Pliva Hrvatska D.O.O. Pharmaceutically acceptable salts and polymorphic forms of sildenafil
CN103122001A (zh) * 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
US8481525B2 (en) * 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
US8263596B2 (en) * 2010-04-06 2012-09-11 University Health Network Kinase inhibitors and method of treating cancer
CN102892766A (zh) * 2010-04-06 2013-01-23 大学健康网络 激酶抑制剂和用其治疗癌症的方法
US8481533B2 (en) * 2010-04-06 2013-07-09 University Health Network Kinase inhibitors and method of treating cancer
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012121764A1 (en) * 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional Characterization of CFI-400945,a Polo-like Kinase 4 Inhibitor,as a Potential Anticancer Agent;Jacqueline M. Mason et al.;《Cancer Cell》;20140811;第26卷;163-176 *

Also Published As

Publication number Publication date
US10392374B2 (en) 2019-08-27
TW201609717A (zh) 2016-03-16
ES2718603T3 (es) 2019-07-03
PT3057965T (pt) 2019-04-23
IL245038B (en) 2019-11-28
RS58413B1 (sr) 2019-04-30
US20200140428A1 (en) 2020-05-07
TR201902875T4 (tr) 2019-03-21
TWI659952B (zh) 2019-05-21
US10472353B2 (en) 2019-11-12
EA031569B1 (ru) 2019-01-31
CN105764899A (zh) 2016-07-13
KR20160070106A (ko) 2016-06-17
JP2016537326A (ja) 2016-12-01
DK3057965T3 (en) 2019-04-01
LT3057965T (lt) 2019-03-12
MX359069B (es) 2018-09-12
EP3057965A1 (en) 2016-08-24
SI3057965T1 (sl) 2019-04-30
KR20210137251A (ko) 2021-11-17
AU2014336929B9 (en) 2019-03-21
AU2014336929B2 (en) 2018-11-22
KR102395737B1 (ko) 2022-05-10
US9884855B2 (en) 2018-02-06
US10919886B2 (en) 2021-02-16
MX2016004963A (es) 2016-06-28
US11667627B2 (en) 2023-06-06
US20190248775A1 (en) 2019-08-15
WO2015054793A1 (en) 2015-04-23
HRP20190564T1 (hr) 2019-05-17
CA2926845A1 (en) 2015-04-23
CY1121484T1 (el) 2020-05-29
ME03377B (me) 2020-01-20
SMT201900124T1 (it) 2019-05-10
HUE043194T2 (hu) 2019-08-28
US20160264559A1 (en) 2016-09-15
EP3057965A4 (en) 2017-05-24
NZ718744A (en) 2021-07-30
US20180155335A1 (en) 2018-06-07
EA201690755A1 (ru) 2016-09-30
EP3057965B1 (en) 2019-01-02
SG11201602783SA (en) 2016-05-30
KR20220063299A (ko) 2022-05-17
CA2926845C (en) 2023-06-13
CN113248486A (zh) 2021-08-13
US20210269428A1 (en) 2021-09-02
PL3057965T3 (pl) 2019-08-30
IL245038A0 (en) 2016-05-31
JP6492072B2 (ja) 2019-03-27

Similar Documents

Publication Publication Date Title
US11667627B2 (en) Salt and crystal forms of PLK-4 inhibitor
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
US11878980B2 (en) Solid forms of TTK inhibitor
JP7705351B2 (ja) ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
EA044843B1 (ru) Кристаллическая форма ингибитора plk4

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant